Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:LNTHNASDAQ:RVMDNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$35.89-1.2%$33.91$21.62▼$39.47$5.96B1.082.27 million shs3.26 million shsLNTHLantheus$102.70+0.9%$97.80$65.76▼$126.89$7.03B0.2950,892 shs836,798 shsRVMDRevolution Medicines$41.47+7.0%$37.42$29.17▼$62.40$5.82B1.371.43 million shs2.87 million shsVCELVericel$38.74-2.5%$45.38$37.04▼$63.00$1.94B1.61393,599 shs447,174 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-1.16%+7.10%+2.22%-1.16%+44.25%LNTHLantheus+0.91%+2.07%+6.80%+12.70%+56.65%RVMDRevolution Medicines+6.96%+13.43%+11.03%+1.34%+15.32%VCELVericel-2.49%-5.21%-12.94%-35.55%-15.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.5387 of 5 stars4.51.00.03.92.74.20.6LNTHLantheus4.432 of 5 stars3.51.00.04.23.52.51.9RVMDRevolution Medicines3.7887 of 5 stars3.50.00.04.73.72.50.0VCELVericel2.2858 of 5 stars3.50.00.00.02.90.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$53.0047.67% UpsideLNTHLantheus 3.00Buy$129.4326.03% UpsideRVMDRevolution Medicines 3.00Buy$66.6760.76% UpsideVCELVericel 3.00Buy$60.8657.09% UpsideCurrent Analyst Ratings BreakdownLatest VCEL, RVMD, LNTH, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $53.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/31/2025BBIOBridgeBio PharmaRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.003/24/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $50.003/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.003/3/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $73.003/3/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$67.00 ➝ $61.002/28/2025VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M30.71N/AN/A($7.71) per share-4.65LNTHLantheus$1.53B4.58$8.57 per share11.98$11.91 per share8.62RVMDRevolution Medicines$742K10,390.58N/AN/A$11.09 per share3.74VCELVericel$237.22M8.19$0.01 per share3,081.95$4.73 per share8.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$2.85N/AN/AN/A-241.44%N/A-75.69%4/29/2025 (Estimated)LNTHLantheus$326.66M$4.3717.0916.28N/A28.57%44.29%23.52%5/7/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/6/2025 (Estimated)VCELVericel-$3.18M$0.18645.7788.05N/A1.56%1.48%0.96%5/8/2025 (Estimated)Latest VCEL, RVMD, LNTH, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/8/2025Q1 2025VCELVericel-$0.09N/AN/AN/A$53.86 millionN/A5/7/2025Q1 2025LNTHLantheus$1.64N/AN/AN/A$377.37 millionN/A4/29/2025Q1 2025BBIOBridgeBio Pharma-$0.90N/AN/AN/A$57.14 millionN/A2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/20/2025Q4 2024BBIOBridgeBio Pharma-$1.09-$1.31-$0.22-$1.40$4.04 million$5.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67LNTHLantheusN/A1.651.56RVMDRevolution MedicinesN/A14.2414.24VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%LNTHLantheus99.06%RVMDRevolution Medicines94.34%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma24.66%LNTHLantheus1.50%RVMDRevolution Medicines8.00%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.86 million143.29 millionOptionableLNTHLantheus70068.48 million68.48 millionOptionableRVMDRevolution Medicines250185.91 million154.76 millionOptionableVCELVericel30050.14 million46.79 millionOptionableVCEL, RVMD, LNTH, and BBIO HeadlinesRecent News About These CompaniesIntrinsic Edge Capital Management LLC Sells 11,946 Shares of Vericel Co. (NASDAQ:VCEL)April 28 at 6:28 AM | marketbeat.comNatixis Invests $1.71 Million in Vericel Co. (NASDAQ:VCEL)April 25, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Trading Down 3.5% - Here's WhyApril 24, 2025 | marketbeat.comVericel to Report First-Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comVericel Co. (NASDAQ:VCEL) Shares Acquired by Wells Fargo & Company MNApril 23, 2025 | marketbeat.comRenaissance Technologies LLC Buys 9,200 Shares of Vericel Co. (NASDAQ:VCEL)April 22, 2025 | marketbeat.comBrokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $60.86April 21, 2025 | americanbankingnews.com623,440 Shares in Vericel Co. (NASDAQ:VCEL) Purchased by Champlain Investment Partners LLCApril 20, 2025 | marketbeat.comRaymond James Financial Inc. Purchases New Stake in Vericel Co. (NASDAQ:VCEL)April 20, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from BrokeragesApril 20, 2025 | marketbeat.comXTX Topco Ltd Makes New $1.14 Million Investment in Vericel Co. (NASDAQ:VCEL)April 18, 2025 | marketbeat.comBessemer Group Inc. Increases Stake in Vericel Co. (NASDAQ:VCEL)April 18, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Bought by Townsquare Capital LLCApril 17, 2025 | marketbeat.comCerity Partners LLC Reduces Holdings in Vericel Co. (NASDAQ:VCEL)April 16, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Sold by Fmr LLCApril 16, 2025 | marketbeat.comVericel price target lowered to $60 from $63 at BTIGApril 15, 2025 | markets.businessinsider.comInvesco Ltd. Has $122.90 Million Stake in Vericel Co. (NASDAQ:VCEL)April 15, 2025 | marketbeat.comGeode Capital Management LLC Purchases 12,062 Shares of Vericel Co. (NASDAQ:VCEL)April 15, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Stock Position Lifted by LPL Financial LLCApril 14, 2025 | marketbeat.comTruist Financial Lowers Vericel (NASDAQ:VCEL) Price Target to $51.00April 13, 2025 | marketbeat.comNeuberger Berman Group LLC Buys 55,555 Shares of Vericel Co. (NASDAQ:VCEL)April 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCEL, RVMD, LNTH, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$35.89 -0.42 (-1.16%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$35.27 -0.62 (-1.72%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Lantheus NASDAQ:LNTH$102.70 +0.93 (+0.91%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$102.94 +0.24 (+0.24%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Revolution Medicines NASDAQ:RVMD$41.47 +2.70 (+6.96%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$41.75 +0.28 (+0.68%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Vericel NASDAQ:VCEL$38.74 -0.99 (-2.49%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$37.03 -1.71 (-4.40%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
